title: HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.
abstract: BACKGROUND
  Since the initial reports of human epidermal growth factor receptor 2 (HER-2) expression as being prognostic in osteosarcoma, numerous small studies varying in the interpretation of the immunohistochemical (IHC) staining patterns have produced conflicting results. The Children's Oncology Group therefore embarked on a prospective biology study in a larger sample of patients to define in osteosarcoma the prognostic value of HER-2 expression using the methodology employed in the initial North American study describing an association between HER-2 expression and outcome.
  
  
  METHODS
  The analytic patient population was comprised of 149 patients with newly diagnosed osteosarcoma, 135 with localized disease and 14 with metastatic disease, all of whom had follow up clinical data. Paraffin embedded material from the diagnostic biopsy was stained with CB11 antibody and scored by two independent observers. Correlation of HER-2 IHC score and demographic variables was analyzed using a Fisher's exact test and correlation with survival using a Kaplan-Meier analysis.
  
  
  RESULTS
  No association was found with HER-2 status and any of the demographic variables tested including the presence or absence of metastatic disease at diagnosis. No association was found between HER-2 status and either event free survival or overall survival in the patients with localized disease.
  
  
  CONCLUSIONS
  HER-2 expression is not prognostic in osteosarcoma in the context of this large prospective study. HER-2 expression cannot be used as a basis for stratification of therapy. Identification of potential prognostic factors should occur in the context of large multi-institutional biology studies.
authors.affiliation: Department of Pediatrics, The Children's Hospital at Montefiore and the Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Sarah
authors.initials: S
authors.lastname: Gorlick
authors.forename: Donald A
authors.initials: DA
authors.lastname: Barkauskas
authors.forename: Mark
authors.initials: M
authors.lastname: Krailo
authors.forename: Sajida
authors.initials: S
authors.lastname: Piperdi
authors.forename: Rebecca
authors.initials: R
authors.lastname: Sowers
authors.forename: Jonathan
authors.initials: J
authors.lastname: Gill
authors.forename: David
authors.initials: D
authors.lastname: Geller
authors.forename: R Lor
authors.initials: RL
authors.lastname: Randall
authors.forename: Katherine
authors.initials: K
authors.lastname: Janeway
authors.forename: Cindy
authors.initials: C
authors.lastname: Schwartz
authors.forename: Holcombe
authors.initials: H
authors.lastname: Grier
authors.forename: Paul A
authors.initials: PA
authors.lastname: Meyers
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
authors.forename: Mark
authors.initials: M
authors.lastname: Bernstein
authors.forename: Neyssa
authors.initials: N
authors.lastname: Marina
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Her-2; human epidermal growth factor receptor; immunohistochemistry; osteosarcoma
references.citation: Mod Pathol. 2001 Dec;14(12):1277-83
references.pmid: 11743051
references.citation: Eur J Cancer. 2004 May;40(7):963-70
references.pmid: 15093570
references.citation: Cancer Res. 2004 Mar 15;64(6):2047-53
references.pmid: 15026342
references.citation: Breast Cancer Res Treat. 1998;52(1-3):65-77
references.pmid: 10066073
references.citation: Cancer. 2009 Apr 1;115(7):1531-43
references.pmid: 19197972
references.citation: Eur J Cancer. 2005 Jun;41(9):1349-61
references.pmid: 15913990
references.citation: Cancer. 1996 Jan 1;77(1):71-8
references.pmid: 8630943
references.citation: J Clin Oncol. 2007 May 20;25(15):2057-62
references.pmid: 17513810
references.citation: Lab Invest. 2004 Jan;84(1):113-21
references.pmid: 14631380
references.citation: Cancer. 2002 Mar 1;94(5):1397-404
references.pmid: 11920494
references.citation: Oncol Rep. 2004 Jul;12(1):125-8
references.pmid: 15201972
references.citation: Urology. 2004 Apr;63(4):786-90
references.pmid: 15072912
references.citation: Cancer. 2004 May 1;100(9):1936-42
references.pmid: 15112275
references.citation: Semin Oncol. 2000 Dec;27(6 Suppl 11):53-63; discussion 92-100
references.pmid: 11236029
references.citation: N Engl J Med. 1995 Nov 23;333(21):1380-5
references.pmid: 7477118
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Pharmacol Ther. 2013 Jan;137(1):89-99
references.pmid: 22983152
references.citation: Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18
references.pmid: 21317869
references.citation: J Pediatr Hematol Oncol. 2003 Jan;25(1):27-32
references.pmid: 12544770
references.citation: J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
references.pmid: 11106683
references.citation: Oncol Lett. 2012 Apr 1;3(4):797-801
references.pmid: 22740996
references.citation: Pancreas. 1997 Apr;14(3):229-36
references.pmid: 9094152
references.citation: J Pediatr Hematol Oncol. 2009 Apr;31(4):245-51
references.pmid: 19346874
references.citation: Cancer. 2001 Aug 1;92(3):677-83
references.pmid: 11505415
references.citation: Pediatr Dev Pathol. 2005 Sep-Oct;8(5):525-32
references.pmid: 16211448
references.citation: Oncology. 2001;60(4):361-6
references.pmid: 11408805
references.citation: Expert Opin Pharmacother. 2010 Jan;11(1):51-61
references.pmid: 20001429
references.citation: J Clin Oncol. 1999 Sep;17(9):2781-8
references.pmid: 10561353
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2545-51
references.pmid: 22665540
references.citation: Cancer Invest. 2004;22(1):16-24
references.pmid: 15069760
references.citation: Pediatr Blood Cancer. 2008 Aug;51(2):222-7
references.pmid: 18421709
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: Clin Cancer Res. 2002 Mar;8(3):788-93
references.pmid: 11895910